coMra-Therapy in Treating Multiple Sclerosis Pain and other Degenerative Symptoms

Written by: Charles Mitchley

coMra-Therapy in Treating Multiple Sclerosis Pain and other Degenerative Symptoms

ABSTRACT

This report describes the results of use of the Delta Laser in treating Multiple Sclerosis. The case study participant, a 50 year old female, was diagnosed with Multiple Sclerosis in 1999. She experienced 1-2 attacks per year that led to permanent neurological damage. Starting in September 2010, daily coMra-Therapy treatments resulted in a very significant reduction in a wide variety of different types of pain, and an improvement across a wider variety of symptoms, including greater vitality, increased coordination and balance, mobility and physical function.

Her use of medication for symptom management and especially for pain, has substantially reduced. In her own words:

... whilst all of my MS symptoms have not disappeared and although pain often makes its presence felt in a strong manner, the use of the Delta has allowed these symptoms to be short lived and be managed.

The Delta allows me to continue with a very good quality of life – working, gardening, going for long walks, shopping, cooking, dressing, bathing – activities that many MS sufferers do not have the luxury of doing.

INTRODUCTION

Multiple Sclerosis (MS) is a very debilitating chronic disease that attacks the central nervous system and leads to a wide variety of neurological symptoms experienced throughout the body [1]. It damages the myelin sheath, the material that surrounds and protects the nerve cells. This damage increases the energy requirement of neurons, resulting in a chronic state of virtual hypoxia [2]. As MS progresses, the symptomatology tends to increase. Problems with walking, vision and speech and very severe pain are some of the most important symptoms among MS patients [4]. Attacks of MS can result in permanent neurological damage.

Currently there is no known cure for MS. Treatments are therefore limited to attempting to return function after an attack, prevent new attacks, or to prevent disability. However, MS medications can have adverse effects or be poorly tolerated and at best slow the disease, but they do not stop it or make the patient feel better [5]. A treatment modality that is free of side-effects, as well as being effective, is therefore to be welcomed.

Coherent Multi-Radiance Therapy is a therapeutic modality with a vast potential in treating neurologic diseases, because of the complete absence of any negative side effects, as well as the proven neuroprotective effects of low level radiances used in coMra-Therapy.

In this case study a female participant with relapsing remitting MS has been using coMra-Therapy for two and half years. The treatments were performed at home by the participant, and the study was monitored by the author of this report. Treatments commenced on 1 September 2010 in Cape Town. This report describes short term and long term improvements of the patient's symptoms and overall condition as recorded in the participant's diary, as well as changes in medication use.

CASE PRESENTATION

The participant, a female, aged 50, had a suspected stroke in 1998, and then again in 1999 and was subsequently diagnosed with MS in May 1999, by Prof. Brian Keyes, Professor of Neurology at Groote Schuur Hospital, Cape Town. She says that she had on average between 1 and 2 relapses per year since then, mostly resulting in permanent damage.

On 1 October 2008, the participant began a 2 year blind trial in a clinical study for a new pharmaceutical drug aimed to reduce the frequency of relapses. The study was performed through Groote Schuur Hospital, under the direction of Professor Jeanine Heckmann and Sister Fiona Drummond.

From October 2008 till August 2010 she experienced relapses and onsets of various new symptoms. She used a walking stick during this period, because of her lack of balance and also her pain. During this time, she underwent comprehensive monthly tests at the hospital to evaluate her reactions to the drug.

On 7 September 2010, the participant began a 2 year open label clinical trial of the product. From this time, hospital evaluations were reduced to once every 3 months.

The participant's main symptoms as at 30/08/2010 were:

Deaf in left ear, fatigue, blurred vision, difficulty walking, loss of muscular strength in hands and arms, loss of balance, inability to digest food properly, inability to swallow correctly (choking), skin pain (sensitivity to touch/burning), numbness and pins & needles, MS-Hug (intense pain around abdomen/back), arthritis and limited movements in joints of left hand, heart conditions –IST (Inappropriate Sinus Tachycardia), high blood pressure (MS related), GTT gall bladder/bile output high.

The participant experiences both chronic and acute pain. Much of the chronic pain radiates down the arms, hip joints, leg, ankles and face. Those pains vary but are otherwise constant. The acute pains come and go. Some of these types of pain affect the whole body, and are likened by the participant to the onset of flu, and they also cause fatigue. Acute pain also comes in the form of shooting pains, sharp and quick, like an electric shock. These were common in the hands, face and back. Fluctuations in temperature seem to exacerbate pain. Since the pains were worse at night, sleep was disturbed, which added to the fatigue.

Unlike many MS symptoms that come and go, the chronic pain associated with MS is constant in many patients. In the case of the participant the chronic pain changes a lot in intensity.

TREATMENT

On 1/9/2010, after agreement from Professor Heckmann at Groote Schuur Hospital, the participant started treating herself at home with coMra-Therapy.

The treatments program was based on the treatment protocol set out in the User Guide for MS (Neurology 10), and was adapted as necessary.

Sudden onset of specific localized pain was treated by using the Delta as described below.

In addition, other conditions, such as the arthritis in her left hand, were treated using the respective treatments set out in the User Guide.

Treatments were carried out morning and evening, but also more frequently if she felt tired and drained throughout the day.

The treatments continued as described below.

Headaches and migraines

  • Universal 1 (Head).
  • Twice a day.
  • At the onset of treatments, this was done twice daily for approximately 2 months. As the recurring headaches stopped, treatment was only used intermittently, at the onset of a headache. During treatment it took between 10-20 minutes for the pain to ease.

Insomnia, fatigue, stress

  • Universal 5 (Somatic Biostimulation, Routine 2).
  • Twice a day.
  • During times of excessive fatigue (during hot weather), this treatment was increased to three times a day.

For energy and feeling of well-being

  • Universal 3 (Blood).
  • Once a day, normally in the morning.
  • During times of excessive fatigue and lethargy, times per point were increased to 2 minutes per point.

(OR Universal 7 – Nervous system, which is a combination of Universal 3 and 5).

Tachycardia and hypertension

  • Cardiology 2 and Cardiology 3.
  • Once a day, alternating between 2 and 3.

Pain, lethargy, exhaustion

  • Universal 4 (Somatic Biostimulation, Routine 1).
  • Once a day, one section per day over 6 days. (At March 2013 she only does this treatment twice a month).

Bruises and sprains from falls

  • For the cuts, scanning above the area (not touching the cut) for 3-5 minutes, depending on the intensity of the cut, on 1000 Hz.
  • For the sprains and bruises, hold the Delta on the area for 3 minutes at 5 Hz and then 3 minutes at 50 Hz.
  • Two – three times a day until healing occurred.

Arthritis in knee and fingers

  • Twice a day.
  • Scan the entire area or hold the Delta on specific points.
  • 5 Hz, 2 minutes, 50 Hz, 2 minutes, Variable, 2 minutes.

Sinusitis and rhinitis

  • Otorhinilaryngology 1 (without using the probe).
  • Scanning the sinus areas below the eyes, 5 Hz for 2 minutes each side.
  • Twice a day until cleared (this normally only requires two treatments).

Additional pain treatment

  • In addition to the daily treatments mentioned above, if required, specific areas of pain are treated twice daily, 5 and 50 Hz for 5 minutes per point.

RESULTS

Treatments began on 1/9/2010.

The participant kept a written record of her progress. Improvements were noted as follows:

05/9/2010:_ first full and deep sleep in 10 years; no stomach pain for 1st time in about 7 years; fatigue reduced.

7/9/2010: able to bend and do gardening without experiencing pain. After treating hips (Treatment 71), was able to work in the kitchen without using the chair.

7/9/2010: started taking the open label of the trial drug. Possibly, I was previously on a placebo, as I started to experience headaches and other symptoms. I stopped using the Delta: the symptoms persisted and my energy levels dropped.

15/9/2010: started treatments again with the Delta.

17/9/2010: energy returned, the Delta was also helping to alleviate my headaches.

21/9/2010: headaches abated, and now only occur intermittently. Using the Delta makes the headaches stop immediately, or within a short period after. Any symptom treated with the Delta disappeared within 20 minutes–1/2 hour.

21/9/2010: during this time the Delta was used to treat the swelling of joints on my fingers – arthritis. This was successful. Now it does not re-occur very often. When it does, after treatments with the Delta, the problem is resolved again.

26/10/2010: now I no longer need to use the walking stick, as my balance was restored and pain minimal in legs.

26/10/2010: hospital test results revealed bile count down by 30 points. No other treatment was received for my gall bladder, other than using the Delta.

31/11/2010: headaches have not returned.

10/12/2010: treatments have enabled me to handle the heat of the summer months. I suffered no headaches, no excessive fatigue, no muscle weaknesses.

18/1/2011 onwards: I continued to use the Delta during 2011 with excellent results, and with the knowledge of Prof Heckmann. My improvements continued.

8/6/2012: Continued treatments with the Delta, together with short rest periods, (normally of 1 week), have restored many levels of improvement in my health. I am able to go out without using the walking stick, I have great improvement in pain levels, I suffer from no fatigue, and I am able to work a full day without resting.

6/3/2013: Treatments (Universal 2, 4 and 5) continue on a daily basis. However, I find that I can take longer breaks in-between treatments. Other treatments are only done as required. My headaches have not returned, and together with taking Amitriptyline intermittently my pain is manageable. Should I experience bad bouts of pain, I increase my treatments and within 2 days I am back to normal. I do not use the walking stick. I continue to work a full day, much of which is spent on my feet and I do not rest in the afternoons. The allergic rhinitis is under control.

During my hospital visit in December 2012, my bile count (gall bladder) was normal, my cholesterol within normal range and sugar levels were within normal range. No vitamin or mineral deficiencies noted (no supplements had been taken either). There was a bit of a problem with my mobility, but that was put down to the year end and a long run of teaching on my feet. I have started Pilates and Yoga classes, (something that I could not do before).

I would like to note that I have had no infections (colds, flu, or gastric infections etc.) in over 2 years. I believe this is due to the constant treatments with the Delta, especially since I was prone to many infections in the past.

In conclusion, whilst all of my MS symptoms have not disappeared and although pain often makes its presence felt in a strong manner, the use of the Delta has allowed these symptoms to be short lived and be managed.

The Delta allows me to continue with a very good quality of life – working, gardening, going for long walks, shopping, cooking, dressing, bathing – activities that many MS sufferers do not have the luxury of doing.

Changes in Medication Use

Prior to starting coMra-Therapy treatments the participant used numerous drugs (see below) in an attempt to ease and alleviate the pains and deal with the tachycardia, hypertension and other symptoms. The participant experienced many side effects from these medications and the drugs were not well tolerated. However, since starting treatments with the Delta Laser in September 2010 she was able to significantly reduce her reliance on painkilling tablets.

  • Medication August 2008 – December 2011:

    • Pain:

      • Carbamazepine (Tegretol) 200mg
      • Lyrica
      • Lomatrigine
      • Tramacet
      • Rivotril
    • Incontinence:
      • Oxybutynin
    • Body itch/skin sensitivity:
      • Cilift
    • Tachycardia and Hypertension:
      • Pharmapress 10mg
      • Atenelol 50mg
      • Amlodac 5mg
      • Amlodipine (Amlate 10mg)
      • Ciplatec 5mg
    • Cholesterol:
      • Simvastatin 20mg
  • Medication March 2013:
    • Pain:
      • Tripiline
      • Tramacet
    • Tachycardia and Hypertension:
      • Atenelol
      • Fortzaar
      • Carzin
    • Supplements:
      • Calciferol
    • MS:
      • Biogen BG12

DISCUSSION

To our knowledge use of noninvasive biostimulatory therapies for treating MS symptoms is not widespread. In 2003 a team of doctors and scientists from the Laser Diagnostics and Therapy Center of the Technical University of Łódź reported various therapeutic benefits of Low Level Laser Therapy for MS patients [6; 7]. They reported pain relief effects and improvement of physical function. Basic research, however, strongly supports therapeutic potential of low level lasers for various neurodegenerative conditions [8; 9; 10; 11]. Photobiomodulation has been shown to decrease inflammatory messengers in MS models [12].

In this case study coMra-Therapy demonstrated remarkable healing effects across a wide range of MS symptoms in the participant. Already during the first week of therapy the short term benefits of coMra-Therapy for acute pain relief, restoring sleep and digestion were very pronounced. Although the damaged to hearing and vision sustained during previous MS attacks has not been remedied, longer term improvements in walking, fatigue levels and muscle tone achieved after 2-3 months of coMra-Therapy and continuing improvements during the next two years suggest a drastic change in the course of the disease.

Of particular importance are the growing sense of self-sufficiency in the participant and the confidence in the ability to take care of her own health. This is a welcome change from a generally depressive and pessimistic attitude of many chronic MS sufferers. The decrease in both acute attacks and chronic pain naturally led the participant to coming off a substantial amount of the medication taken before starting coMra-Therapy, thus easing the financial burden of the disease.

In this case study use of coMra-Therapy reached up to several hours daily during the first 18 months. Despite very extensive treatments no negative side effects were noticed. The ability to increase break periods between treatment courses from the second year onward while maintaining improvements also shows the absence of dependency of the body on therapy.

CONCLUSION

This case study has shown coMra-Therapy to be effective in the treatment of pain and other symptoms in the Relapsing-Remitting form of Multiple Sclerosis.

ACKNOWLEDGEMENTS

The author thanks the participant, Mrs Cheryl Terblanche, for her willingness and assistance in keeping records for this study and for making these available to us.

REFERENCES

1. Wikipedia. 2013. Multiple sclerosis [cited April 9 2013]. Available from http://en.wikipedia.org/wiki/Multiple_sclerosis.

2. Trapp, B.D., et al. 2009. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. The Lancet Neurology no. 8 (3):280-291. doi: 10.1016/S1474-4422(09)70043-2.

3. Heesen, C., et al. 2008. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Multiple Sclerosis no. 14 (7):988-991. doi: 10.1177/1352458508088916.

4. Kalia, L.V., et al. 2005. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Multiple Sclerosis no. 11 (3):322-327. doi: 10.1191/1352458505ms1168oa.

5. Olek, M. 2013. Treatment of relapsing-remitting multiple sclerosis in adults. [cited April 09, 2013]. Available from http://www.uptodate.com/contents/treatment-of-relapsing-remitting-multiple-sclerosis-in-adults.

6. Peszynski-Drews, C., et al. 2003. Laser biostimulation of patients suffering from multiple sclerosis in respect to the biological influence of laser light. Paper read at Laser Technology VII: Applications of Lasers. doi: 10.1117/12.520611.

7. Gruszczyńska, D.K. 2010. Laser Treatment for Multiple Sclerosis. The Warsaw voice, June 17, 2010. Available from http://www.warsawvoice.pl/WVpage/pages/article.php/22147/article.

8. Naeser, M.A., et al. 2011. Potential for Transcranial Laser or LED Therapy to Treat Stroke, Traumatic Brain Injury, and Neurodegenerative Disease. Photomedicine and Laser Surgery no. 29 (7):443-446. doi: 10.1089/pho.2011.9908.

9. Huang, Y.-Y., et al. 2010. Low-Level Laser Therapy in Stroke and Central Nervous System. In Handbook of Photonics for Biomedical Science, edited by V.V. Tuchin, 717-737. Boca Raton, FL: CRC Press.

10. Anders, J.J. 2009. The potential of light therapy for central nervous system injury and disease. Photomedicine and Laser Surgery no. 27 (3):379-380. doi: 10.1089/pho.2009.0053.

11. Hashmi, J.T., et al. 2010. Role of Low-Level Laser Therapy in Neurorehabilitation. PM&R no. 2 (12, Supplement):S292-S305. doi: 10.1016/j.pmrj.2010.10.013.

12. Muili, K.A., et al. 2012. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light. PLoS One no. 7 (1):e30655. doi: 10.1371/journal.pone.0030655.

For a comprehensive list of User Cases and Testimonials, please visit our searchable database